trending Market Intelligence /marketintelligence/en/news-insights/trending/87nan6ysjlj_vjvel5q7za2 content esgSubNav
In This List

Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

Mylan NV said it acquired the global rights to two Novartis AG respiratory drugs in a deal valued at about $463 million.

Novartis' TOBI Podhaler and TOBI solution are meant to treat cystic fibrosis, a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.

Mylan expects to settle approximately $240 million of the deal value this year.

The acquisition strengthens Mylan's portfolio of respiratory drugs.